scholarly journals Current and future cholera vaccines

Vaccine ◽  
2020 ◽  
Vol 38 ◽  
pp. A118-A126 ◽  
Author(s):  
Hanif Shaikh ◽  
Julia Lynch ◽  
Jerome Kim ◽  
Jean-Louis Excler
Keyword(s):  
2007 ◽  
Vol 7 (3) ◽  
pp. 176-178 ◽  
Author(s):  
Shahjahan Kabir
Keyword(s):  

Author(s):  
Y. S. Nimbkar ◽  
R. S. Karbhari ◽  
S. Cherian ◽  
N. G. Chanderkar ◽  
R. P. Bhamaria ◽  
...  

mSphere ◽  
2019 ◽  
Vol 4 (4) ◽  
Author(s):  
Ana A. Weil ◽  
Crystal N. Ellis ◽  
Meti D. Debela ◽  
Taufiqur R. Bhuiyan ◽  
Rasheduzzaman Rashu ◽  
...  

ABSTRACT Vibrio cholerae infection provides long-lasting protective immunity, while oral, inactivated cholera vaccines (OCV) result in more-limited protection. To identify characteristics of the innate immune response that may distinguish natural V. cholerae infection from OCV, we stimulated differentiated, macrophage-like THP-1 cells with live versus heat-inactivated V. cholerae with and without endogenous or exogenous cholera holotoxin (CT). Interleukin 23A gene (IL23A) expression was higher in cells exposed to live V. cholerae than in cells exposed to inactivated organisms (mean change, 38-fold; 95% confidence interval [95% CI], 4.0 to 42; P < 0.01). IL-23 secretion was also higher in cells exposed to live V. cholerae than in cells exposed to inactivated V. cholerae (mean change, 5.6-fold; 95% CI, 4.4 to 11; P < 0.001). This increase in IL-23 secretion was more marked than for other key innate immune cytokines (e.g., IL-1β and IL-6) and dependent on exposure to the combination of both live V. cholerae and CT. While IL-23 secretion was reduced following stimulation with either heat-inactivated wild-type V. cholerae or a live isogenic ctxAB mutant of V. cholerae, the addition of exogenous CT restored IL-23 secretion in combination with the live isogenic ctxAB mutant V. cholerae, but not when it was paired with stimulation by heat-inactivated V. cholerae. The posttranslational regulation of IL-23 under these conditions was dependent on the activity of the cysteine protease cathepsin B. In humans, IL-23 promotes the differentiation of Th17 cells to T follicular helper cells, which maintain and support long-term memory B cell generation after infection. Based on these findings, the stimulation of IL-23 production may be a determinant of protective immunity following V. cholerae infection. IMPORTANCE An episode of cholera provides better protection against reinfection than oral cholera vaccines, and the reasons for this are still under study. To better understand this, we compared the immune responses of human cells exposed to live Vibrio cholerae with those of cells exposed to heat-killed V. cholerae (similar to the contents of oral cholera vaccines). We also compared the effects of active cholera toxin and the inactive cholera toxin B subunit (which is included in some cholera vaccines). One key immune signaling molecule, IL-23, was uniquely produced in response to the combination of live bacteria and active cholera holotoxin. Stimulation with V. cholerae that did not produce the active toxin or was killed did not produce an IL-23 response. The stimulation of IL-23 production by cholera toxin-producing V. cholerae may be important in conferring long-term immunity after cholera.


2002 ◽  
Vol 35 (10) ◽  
pp. 1147-1154 ◽  
Author(s):  
Jean‐François Faucher ◽  
Ronnie Binder ◽  
Michel A. Missinou ◽  
Pierre‐Blaise Matsiegui ◽  
Holger Gruss ◽  
...  

2018 ◽  
Vol 12 (10) ◽  
pp. e0006652 ◽  
Author(s):  
Ashraful Islam Khan ◽  
Ann Levin ◽  
Dennis L. Chao ◽  
Denise DeRoeck ◽  
Dobromir T. Dimitrov ◽  
...  

2014 ◽  
pp. 34-34
Author(s):  
Vivek Singh ◽  
RK Singal ◽  
AK Agarwal
Keyword(s):  

2019 ◽  
Vol 12 (4) ◽  
pp. 1055-1064 ◽  
Author(s):  
Christopher J. H. Davitt ◽  
Stephanie Longet ◽  
Aqel Albutti ◽  
Vincenzo Aversa ◽  
Stefan Nordqvist ◽  
...  

AbstractCholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3–4 million cases globally with 100,000–150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, single-component whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses.


Sign in / Sign up

Export Citation Format

Share Document